NCT04474353View on ClinicalTrials.gov

Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 21, 2021

Primary Completion Date

November 14, 2024

Study Completion Date

November 11, 2025

Conditions
GlioblastomaNewly Diagnosed Glioblastoma
Interventions
DEVICE

Optune

Noninvasive, portable device which generates tumor treating fields (TTFields) manufactured by Novocure

DRUG

Gadolinium

Gadolinium contrast medium

DRUG

Temozolomide

Chemotherapy agent

RADIATION

Stereotactic radiosurgery (SRS)

Standard of Care: SRS (35 Gy in 5 fractions of 7 Gy), 5-day treatment from Day 2

Trial Locations (1)

94304

Stanford University, Stanford

All Listed Sponsors
collaborator

NovoCure Ltd.

INDUSTRY

lead

Stanford University

OTHER